High-content screening (HCS) or high-content analysis (HCA) (also known as cellomics), is a set of analytical techniques that is applied in genetic research and drug discovery processes in order to recognize elements such as peptides, small molecules, or genetic materials (such as RNAi) that have the potential to modify the phenotype of a cell in a certain manner. High-content screening employs a set of analytical procedures such as multi-parameter image processing, automated microscopy, fluorescence imaging, and other visualization processes to get quantitative data from cell populations. The phenotypic alterations may comprise rise or decrease in the production of cellular produces such as proteins, or changes in the morphology of a cell. High-content screening can be employed to analyze whole cells or certain components of cells with simultaneous data collection of numerous factors.
The high-content screening market is anticipated to witness significant growth during the forecast period, owing to the ability of HCS to study several parameters in a complex biological system simultaneously. High-content screening (HCS) is also expected to generate high demand due to its numerous applications in pre-clinical, clinical trial, and later stages of drug development. High-content screening can also be used to calculate cellular toxicity, to recognize and validate new drug targets or new prime combinations, and to propose pathways or molecular targets of orphan compounds. The steep rise in demand for better and cost-effective methods of drug discovery and clinical trials and increased knowledge of pharmacogenetics and pharmacokinetics are factors inclining the clinicians toward high-content screening of certain medications. Rapid increase in the prevalence of complex neurological diseases and genetic disorders has fueled the demand for high-end R&D activities. This, in turn, is anticipated to boost the high-content screening market during the forecast period. Moreover, increasing investment in research and development in cellular science of novel molecules by private and government bodies is expected to propel the HCS market in the near future. In addition, development of innovative tools for health care management is propelling the market further. However, low research and development (R&D) yields, high cost of infrastructure, stringent regulatory framework, and lack of trained resources are some of the restraints for the high-content screening market.
The high-content screening market can be segmented on the basis of product, application, end-user, and region. The product segments include cell imaging systems, flow cytometers, microplates, software, and consumables. Increasing preference to technologically advanced services and innovative products is a factor expected to fuel the high-content screening market during the forecast period. Based on application, the market has been segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Based on end-user, the market can be segmented into pharmaceutical industry, biotechnology industry, educational institutions, government organizations, and contract research organizations (CROs).
Geographically, the high-content screening market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is estimated to hold the major share of the global high-content screening market during the forecast period, due to presence of superior research and health care facilities, strong regional economy, and greater focus on healthcare wellness by the government. This trend has also reflected in other countries. The high-content screening market in Europe is expected to witness growth at a rapid pace in the next few years, due to high consciousness about wellbeing coupled with increasing expenditure on R&D activities in the region. Countries in Asia Pacific such as China, Japan, and India are also poised to be promising markets for high-content screening in the near future. Major factors responsible for the positive outlook for the Asia Pacific market are extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.
Key players in the global high-content screening market include Thermo Fisher Scientific, PerkinElmer Inc., GE Healthcare, Becton, Dickinson and Company (BD), Olympus Corporation, Thorlabs Inc., Merck KGaA, Cell Signaling Technology, Genedata AG, and Yokogawa Electric Corporation.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.